These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 8908380

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.
    Nauck MA, Sauerwald A, Ritzel R, Holst JJ, Schmiegel W.
    Diabetes Care; 1998 Nov; 21(11):1925-31. PubMed ID: 9802745
    [Abstract] [Full Text] [Related]

  • 3. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
    Toft-Nielsen MB, Madsbad S, Holst JJ.
    Diabetes Care; 1999 Jul; 22(7):1137-43. PubMed ID: 10388979
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.
    Rachman J, Barrow BA, Levy JC, Turner RC.
    Diabetologia; 1997 Feb; 40(2):205-11. PubMed ID: 9049482
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes.
    Zander M, Christiansen A, Madsbad S, Holst JJ.
    Diabetes Care; 2004 Aug; 27(8):1910-4. PubMed ID: 15277416
    [Abstract] [Full Text] [Related]

  • 12. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients.
    Nauck MA, Weber I, Bach I, Richter S, Orskov C, Holst JJ, Schmiegel W.
    Diabet Med; 1998 Nov; 15(11):937-45. PubMed ID: 9827848
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function.
    Kielgast U, Holst JJ, Madsbad S.
    Diabetes; 2011 May; 60(5):1599-607. PubMed ID: 21441444
    [Abstract] [Full Text] [Related]

  • 17. Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes.
    Gutniak MK, Svartberg J, Hellström PM, Holst JJ, Adner N, Ahrén B.
    J Intern Med; 2001 Jul; 250(1):81-7. PubMed ID: 11454146
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
    Chow CC, Tsang LW, Sorensen JP, Cockram CS.
    Diabetes Care; 1995 Mar; 18(3):307-14. PubMed ID: 7555472
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.